Waldencast Reports Q4 2025 and FY 2025 Financial Results [Yahoo! Finance]
Waldencast plc - Class A Ordinary Share (WALD)
Company Research
Source: Yahoo! Finance
Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical sees continued revenue acceleration as a result of transformation efforts and continued brand momentum, alongside investments supporting the recent launch of its injectables platform Milk Makeup maintains U.S. consumption growth through distribution expansion, offset by softness in international markets Waldencast advanced its strategic priorities in 2025, entering medical aesthetics, and strengthening its financial flexibility through the sale of the Obagi Japan trademark and the refinancing of its credit facility. As a result, the Company enters 2026 with a strong foundation for successful growth LONDON, March 13, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today reported operating results for the three months ended December 31, 2025 (“Q4 2025”) and year ended December 31, 2025
Show less
Read more
Impact Snapshot
Event Time:
WALD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WALD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WALD alerts
High impacting Waldencast plc - Class A Ordinary Share news events
Weekly update
A roundup of the hottest topics
WALD
News
- Waldencast (WALD) had its price target lowered by Telsey Advisory Group from $3.00 to $2.00. They now have a "market perform" rating on the stock.MarketBeat
- Waldencast (WALD) had its price target lowered by Canaccord Genuity Group Inc. from $4.00 to $2.00. They now have a "buy" rating on the stock.MarketBeat
- Waldencast Reports Q4 2025 and FY 2025 Financial ResultsGlobeNewswire
- Waldencast plc Announces Fourth Quarter and Fiscal Year 2025 Earnings DateGlobeNewswire
- Obagi Medical and Schweiger Dermatology Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™ [Yahoo! Finance]Yahoo! Finance
WALD
Sec Filings
- 3/13/26 - Form 6-K
- 3/13/26 - Form 20-F
- 3/11/26 - Form 6-K
- WALD's page on the SEC website